GenAI Collab Update

Another month and another round of GenAI collaboration and partnership announcements. Pharma and Biotech companies continue to partner with Generative AI companies.

• Absci and Twist Bioscience announce collaboration to design novel antibody using Generative AI. This collaboration brings together Absci’s Generative AI drug creation platform with Twist’s DNA synthesis platform to accelerate the design of a novel therapeutic antibody. Twist Bioscience

• Nxera Pharma and Antiverse announce a multi-target partnership and licensing agreement to design antibodies for G-protein coupled receptors (GPCRs). The collaboration combines Antiverse’s generative AI antibody design expertise, including its proprietary machine-learning-generated ‘epitope-specific libraries,’ with Nxera’s NxWave™ platform, a powerful tool for GPCR target selection, validation and structural determination. Antiverse

• Sapio Sciences and AWS expand their collaboration to make generative AI models readily accessible to scientists and researchers. Sapio Sciences

• Evogene and Google Cloud collaborate to develop a cutting-edge foundation model for generative small molecule de novo design. Evogene

• Genesis is collaborating with NVIDIA to accelerate it’s AI platform, GEMS (Genesis Exploration of Molecular Space). Genesis will leverage NVIDIA’s expertise to make computation more efficient for several neural network architectures relevant to drug discovery. The collaboration will encompass optimizing equivariant neural networks, which are valuable for handling 3D geometric data such as protein and small molecule structures. Genesis

1. Insilico Medicine announces positive topline results of ISM001-055 for the treatment of idiopathic pulmonary fibrosis (IPF) developed using generative AI. EurekAlert 

2. Aizen Therapeutics, an AI-driven biotech company pioneering Mirror Peptides as a class of biologic medicine raises $13M to support their early-stage programs powered by novel drug discovery platform, DaX™.

3. Converge Bio raises $5.5M seed funding. The company who have a platform that offers a bio-LLM library with foundational models across all biological languages, will be using the money to hire, acquire customers, publish a scientific paper on antibody design and train models.

4. Healx, an AI-enabled, clinical-stage biotech company specialising in rare diseases, today announced it will use a Sanofi compound to identify new disease indications using Healnet, Healx’s AI-driven drug discovery platform. Under the agreement, Sanofi will provide data related to a late stage discontinued asset that is being considered for out-licensing. Healx

5. Enveda, a biotechnology company using AI to translate nature into new medicines, closes $130M Series C funding, which will enable delivery of clinical targets, advance their pipeline and discovery programs, and invest in their platform. This news comes on the heels of the company’s first clinical trial and announcement of a foundation model for metabolomics. Enveda

6. Medable, a provider of clinical development technology, announced Medable AI – generative AI capabilities that help sponsors and clinical research organizations build digital and decentralized trials faster with complete visibility and control over technology setup. Medable

7. Archon Biosciences, a pioneer in computationally designed Antibody Cages (AbCs) to unlock powerful therapeutic targets beyond the reach of existing modalities, announced its emergence from stealth with $20 million in seed financing. One of this year’s Nobel Prize in Chemistry laureates Dr. David Baker, co-invented the Archon platform. Archon 

8. Insilico Medicine announced that their multi-year research collaboration with Sanofi from 2022 has yielded an AI-facilitated lead with first-in-class potential against an undruggable transcription factor target for treating oncology diseases. EukerlAlert

Sign up here and catch up on The GenAI Biotech Report: Your monthly update of Generative AI applications in Biotech, Pharma, and Life Sciences.